Effects of spironolactone treatment on an experimental model of chronic aortic valve regurgitation

Authors: Zendaoui, AdnaneLachance, DominicRoussel, ÉliseCouët, JacquesArsenault, Marie
Abstract: BACKGROUND AND AIM OF THE STUDY : Aortic regurgitation (AR) is a disease for which there is currently no effective medical treatment. It has been shown previously in an experimental model of AR that the renin-angiotensin-aldosterone system (RAAS) plays a major role, and that medications blocking the RAAS are effective to protect against left ventricular (LV) hypertrophy and also help to maintain a normal systolic function. The role of aldosterone receptor blockers in this disease has never been evaluated. Thus, the effects were studied of the aldosterone receptor blocking agent spironolactone in a model of chronic AR in rats. METHODS : The effects of a six-month treatment with spironolactone were evaluated in adult Wistar rats with severe AR, compared to sham-operated and untreated AR animals. RESULTS : Spironolactone treatment decreased the total heart weight. In addition, the LV expression of atrial natriuretic peptide mRNA was decreased by spironolactone treatment, as was the expression of collagen 1 and LOX1 mRNAs. Left ventricular fibrosis was decreased by spironolactone treatment. CONCLUSION : Spironolactone protected against volume-overload cardiomyopathy in this model of aortic valve regurgitation. The predominant protective effect was a decrease in myocardial fibrosis.
Document Type: Article de recherche
Issue Date: 1 July 2012
Open Access Date: 14 November 2017
Document version: AM
Permalink: http://hdl.handle.net/20.500.11794/15827
This document was published in: The Journal of heart valve disease, Vol. 21 (4), 478-486 (2012)
ICR
Alternative version: 22953675
Collection:Articles publiés dans des revues avec comité de lecture

Files in this item:
SizeFormat 
Zendaoui et al. JHVD.pdf234.32 kBAdobe PDFView/Open
All documents in CorpusUL are protected by Copyright Act of Canada.